Institute Of Hematology & Blood Diseases Hospital, China

This study is for people aged 14 to 60 with a specific genetic subtype of acute myeloid leukemia (AML) called RUNX1-RUNX1T1. It compares two different doses of a chemotherapy drug (cytarabine) given with another drug (anthracycline) to see which leads to longer survival. The goal…

This study tests a new treatment called BCMA-CART, sometimes combined with a stem cell transplant, for young adults (18-55) newly diagnosed with multiple myeloma. The goal is to see how safe and effective it is at controlling the cancer and achieving deep remission. About 50 part…

This study tests a combination of two drugs (CM336 and isatuximab) in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function and control the cancer. Participants receive three cycles …

This early-stage study tests a personalized cell therapy (CD19 CAR-T) in 15 people with severe autoimmune diseases like lupus that haven't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the…

This study tests whether a dietary supplement called sulforaphane (found in broccoli) can safely help blood cell recovery in adults receiving a cord blood transplant for blood cancers like leukemia or myelodysplastic syndrome. The cord blood used has been frozen for 10 years or m…

This study is for people with a specific, high-risk form of acute lymphoblastic leukemia called Ph-like ALL. Researchers are testing whether adding two targeted drugs (olverembatinib or gecacitinib) to standard chemotherapy and venetoclax can help more patients achieve a deep rem…

This early study tests whether stem cells from donated umbilical cord blood can safely help people whose blood cell counts stay dangerously low after CAR-T cancer therapy. About 15 adults with leukemia, lymphoma, or myeloma will receive the stem cell infusion. The goal is to see …

This study tests two different chemotherapy combinations in adults aged 55 to 75 with acute myeloid leukemia (AML) who are healthy enough for strong treatment. One group gets venetoclax plus azacitidine, the other gets standard drugs (daunorubicin or idarubicin plus cytarabine). …

This early-phase study tests a new type of immune cell therapy (supCD7 CART) for people with relapsed or hard-to-treat blood cancers that carry a specific marker called CD7. The therapy uses specially engineered cells to target and destroy cancer cells. Up to 12 adults aged 18 to…

This study tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia, a rare and aggressive blood cancer. The approach combines standard chemotherapy drugs with two rounds of CAR T-cell therapy and a stem cell transplant. The goal is to see if this i…

This study tests a new drug called CM336, a type of antibody that targets both BCMA and CD3 proteins, in people newly diagnosed with AL amyloidosis. The goal is to see if a low dose can improve blood markers of the disease and to check for side effects. About 21 adults will take …

This early-stage study tests whether a patient's own modified immune cells (CAR-T cells) can control HIV without daily antiviral drugs. Only 3 adults with well-controlled HIV are being enrolled to check safety first. If successful, this approach could lead to a functional cure, m…

This study is for people newly diagnosed with a specific type of leukemia called Ph+ ALL. It tests a treatment plan that uses lower doses of chemotherapy along with targeted drugs (venetoclax, blinatumomab, and olverembatinib) to see if it works well and causes fewer side effects…

This early study tests a new treatment called CD5CART for people with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells that carry a protein called CD5. The mai…

This study compares two antibody drugs, daratumumab and rituximab, in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The main goal is to see which drug better raises platelet counts to safe levels by week 12 wit…

This early study tests whether zoledronic acid, a drug usually used for bone health, can improve anemia in adults with congenital dyserythropoietic anemia (CDA), a rare inherited blood disorder. Only 2 participants will receive the drug intravenously every 4 weeks for 4 doses. Th…

This study tests a new approach for adults newly diagnosed with a specific type of leukemia (Ph-negative B-cell ALL) who cannot tolerate strong chemotherapy. It combines low-dose chemo with targeted immune drugs to try to wipe out cancer cells more safely. The goal is to achieve …

This study tests a new treatment for children and teens with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ ALL). The approach uses a combination of targeted drugs (olverembatinib, blinatumomab, and venetoclax) to reduce the need for traditional chemoth…

This study tests a three-drug combination (obinutuzumab, zanubrutinib, and lenalidomide) as a first treatment for people with mantle cell lymphoma who have never had therapy. About 37 adults aged 18-80 will receive the drugs, and those at higher risk may also get CAR-T cell thera…

This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with acute myeloid leukemia (AML) that has an IDH1 mutation. The goal is to see if this triple therapy can improve remission rates and survival. About 23 participants will receive the …

This study tests a three-drug combination (gilteritinib, venetoclax, and azacitidine) in 66 adults newly diagnosed with acute myeloid leukemia (AML) who have a specific genetic change called FLT3 mutation. The goal is to find the best dose and see how well the treatment controls …

This study tests whether adding the targeted drug venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The goal is to find out which genetic subtypes of AML respond best to this combination. About 380 participants aged 14 t…

This study tests whether a mobile app can help children with acute lymphoblastic leukemia keep their blood counts in a target range during maintenance therapy. About 100 children who have already shown good app use will be randomly assigned to continue with the app or not. The go…

This study is for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The treatment combines targeted drugs, reduced-intensity chemotherapy, and CAR-T cell therapy to deepen remission and reduce side effects. The goal is to improve…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people with untreated follicular lymphoma, a type of blood cancer. The goal is to see how well the treatment shrinks or controls the cancer. About 34 adults with stage II bulky or stag…

This study tests whether adding rituximab to eltrombopag works better than eltrombopag alone for adults with immune thrombocytopenia (ITP) whose platelet counts remain low despite prior treatments. About 224 participants will receive either the combination or eltrombopag alone, a…

This study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, found on faulty immune cells. The goal is to see if it is safe and can help control severe autoimmune diseases like lupus and scleroderma that have not …

This study compares two drugs, daratumumab and rituximab, in children aged 6 to 17 with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. ITP causes low platelet counts, leading to bruising and bleeding. The goal is to see which d…

This study tests whether combining radiation with a bispecific antibody (CM336) can safely treat solitary bone plasmacytoma that has mild bone marrow involvement. About 21 adults with this rare plasma cell disorder will receive the combination therapy. The goal is to control the …

This study tests a powerful two-step treatment for people with an aggressive form of multiple myeloma that didn't respond well to first-line therapy. First, patients receive their own stem cells (a stem cell transplant), followed by an infusion of their own genetically modified i…

This early-phase study tests a new type of cell therapy (CAR19-BCMA CAR-T) for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The main goal is to ch…

This study tests whether adding CAR-T cell therapy after standard chemotherapy can help adults newly diagnosed with a type of leukemia (Ph-negative B-ALL) achieve deeper remission and live longer. About 77 participants will receive the combination treatment. The goal is to reduce…

This early-stage study is testing a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that drive autoimmune diseases like lupus and scleroderma. The therapy is given as a one-time infusion and aims to reset …

This study tests a combination of two drugs, rituximab and daratumumab, in 20 adults with immune thrombocytopenia (ITP) who did not get better with steroids. The goal is to see if the combination can safely raise platelet counts and reduce bleeding. Participants will receive the …

This study tests a new drug (anti-CD38 antibody) in 60 children aged 6 and older with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The drug aims to raise platelet counts safely in kids who haven't improved with standard …

This study tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low or came back after steroid treatment. About 160 participants will receive either t…

This study tests whether a drug called chidamide can help prevent relapse in people with high-risk acute myeloid leukemia (AML) after a stem cell transplant. About 134 adults aged 18-75 who are in remission after transplant will either receive chidamide or be observed. The goal i…

This study tests thalidomide alone as a treatment for symptomatic large granular lymphocytic leukemia (LGLL), a rare blood cancer. About 48 adults will take thalidomide daily for up to 3 cycles; if it doesn't work well enough, methotrexate is added. The goal is to see if thalidom…

This study tests a drug called orelabrutinib in 30 people with a slow-growing blood cancer called marginal zone lymphoma who have not had treatment before. The goal is to see if the drug can shrink or eliminate the cancer. Participants take the drug as a pill, and doctors monitor…

This early-phase study tests a new treatment called universal CD7 CART cells for people with certain blood cancers (acute myeloid leukemia or T-cell leukemia/lymphoma) that have come back or not responded to standard therapy. The treatment uses donor immune cells modified to targ…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) in people newly diagnosed with a rare type of lymphoma that affects the spleen. The goal is to see how well the treatment shrinks or controls the cancer and to check for side effects. Abo…

This study tests a clotting medicine called prothrombin complex concentrate (PCC) to stop bleeding in people with hemophilia A who have developed inhibitors (antibodies that block standard treatment). About 30 participants aged 12 to 65 will receive PCC on-demand during bleeding …

This study tests a combination of three antifungal medicines (liposomal amphotericin B plus posaconazole or isavuconazole) in 60 adults with blood cancers who also have a serious fungal infection called mucormycosis. The goal is to see if the combo can clear the infection and imp…

This study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…

This early-stage study tests whether adding methylene blue to standard care can safely reduce cytokine release syndrome (CRS) and neurotoxicity (ICANS) in 18 adults who developed these side effects after CAR-T or bispecific antibody treatment. Participants receive methylene blue …

This study follows 500 children aged 6–17 with immune thrombocytopenia (ITP), a rare disease where the immune system destroys platelets, causing bruising and bleeding. Researchers will collect data on symptoms, treatments, and recovery over time to build a model that predicts how…

This study tracks 200 people with aplastic anemia who are receiving ATG or ALG therapy for the first time. Researchers will closely monitor side effects like serum sickness, infusion reactions, and organ damage to create better management guidelines. The goal is to improve patien…

This study looks at how well a medicine called L-AmB works for treating serious fungal infections in children and teens with blood cancers who are already taking other antifungal drugs. The goal is to see if it works as well in kids as it does in adults and if it causes fewer kid…

This study aims to understand the health of older adults by comparing those living in nursing homes with those receiving home care. Researchers will track chronic diseases, cancers, and other priority health conditions. The study involves 1500 volunteers aged 60 and older who can…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study looks at 60 people getting a stem cell transplant to see if tests of the autonomic nervous system (which controls things like heart rate) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have nerve function tests before…

This study is a registry for 100 adults and adolescents with hemophilia who are already prescribed marstacimab. The main goal is to learn whether patients prefer a simple shot under the skin (subcutaneous) over the usual intravenous injections, and to measure how much the treatme…